1. Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival 
Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li, MD, Zhen-fa Zhang, MD, PhD, Yue-song Yin, MD, Chang-li Wang, MD, PhD 
The Annals of Thoracic Surgery 
Volume 99, Issue 4, Pages (April 2015)
DOI: /j.athoracsur
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Typical expression images of CD34 immunohistochemistry for microvessel density in tissue microarrays. CD34+, ×40.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
(A) Double immunofluorescence staining for CD68 and osteopontin (OPN); immunolocalization of OPN (green) and CD68 (red) frequently overlap (yellow) (×400); (B) Immunolocalization of OPN (green), CD68 (red), which frequently overlap (yellow), and 4′,6-diamidino-2-phenylindole (blue) (×100).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Prognostic significance assessed using Kaplan-Meier survival estimates and log-rank tests. (A, C) Comparisons of overall survival and (B, D) disease-free survival by (A, B) tumor-associated macrophages (TAMs) and (C, D) osteopontin expressed by tumor-associated macrophages (TOPN).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Kaplan-Meier analysis of (A) overall survival and (B) disease-free survival for osteopontin expressed by tumor-associated macrophages TOPN in non-small cell lung carcinoma patients of stage I.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2015 The Society of Thoracic Surgeons Terms and Conditions